Endomagnetics wins first ever ETPN Nanomedicine Award

6 November 2013

Cambridge-based Endomagnetics has been named as one of two winners of the inaugural Nanomedicine Award for its cancer management systems.

The Nanomedicine Award winners were announced during the Nanomedicine Panel Session at BIO-Europe 2013 in Vienna this week.

Launched in June 2013, the Nanomedicine Award has been organised by the European Technology Platform for Nanomedicine (ETPN), together with the EU funded consortium NANOMED2020, to honour the best international nanomedicine innovations. Academia and industry alike were eligible for the first award which covered the fields of diagnostics and imaging, therapeutics and regenerative medicine.

“A global consensus was reached to deliver the award to Endomagnetics for its outstanding development,” said a spokesperson for the Award Review Board, which consists of a panel of respected pharma industry specialists. The Board commented on the concrete potential and promise of nanomedicine.

“Endomagnetics is very honoured to have been selected for an inaugural Nanomedicine Award, particularly given the global candidature and great promise of this convergent industry”, said CEO of Endomagnetics Dr Eric Mayes. “This award enhances the medtech facet of nanomedicine and increases the visibility of our SentiMag and Sienna+ system to potential partners as we develop further across the nanomedicine field.”

As a winner, Endomagnetics made a presentation at the Nanomedicine Panel Discussion during the awards event. In addition, the company will also present during the CLINAM conference 2014 in Basel, Switzerland.

Last month, Endomagnetics was announced as a finalist in the IET Innovation Awards to be judged on 20th November.


To top